Identification of human aldehyde dehydrogenase 1 family member a1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck

Cancer Research

Volumn 67, Issue 21, 2007, Pages 10538-10545

  Visus, Carmen ^a,b   Ito, Diasuke ^a,b   Amoscato, Andrew ^a,b   Maciejewska Franczak, Malgorzata ^a,b   Abdelsalem, Ahmed ^a,b   Dhir, Rajiv ^a,b   Shin, Dong M ^c   Donnenberg, Vera S ^a,b   Whiteside, Theresa L ^a,b   DeLeo, Albert B ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1A1; COMPLEMENTARY DNA; HLA A2 ANTIGEN; RETINAL; RETINOIC ACID; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVITY; GENETIC TRANSFECTION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; VACCINATION;

ALDEHYDE DEHYDROGENASE; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; HEAD AND NECK NEOPLASMS; HEMATOPOIETIC STEM CELLS; HLA-A2 ANTIGEN; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PEPTIDE FRAGMENTS; RNA, MESSENGER;

EID: 35949001624     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1346     Document Type: Article

References (39)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics 2001. CA Cancer J Clin 2001;51:15-36.
2. Viswanatham H, Wilson JA. Alcohol - the neglected risk factor in head and neck cancer. Clin Otolaryngol 2004;29:295-300.
3. Sladek NE. Human aldehyde dehydrogenases: potential pathological, pharmacological and toxicological impact. J Biochem Mol Toxicol 2003;17:7-23.
4. Crabb DW, Matsumoto M, Chang D, You M. Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc Nutr Soc 2004;63:49-63.
5. Duester G. Families of retinoid dehydrogenases regulating vitamin A function. Eur J Biochem 2000;267: 4315-24.
6. Giannini F, Maestro R, Vukosavljevic T, Pomponi F, Boiocchi M. All-trans, 13-cis and 9-cis retinoic acids induce a fully reversible growth inhibition in HNSCC cell lines: implications for in vivo retinoic acid use. Int J Cancer 1997;70:194-200.
7. Simeone AM, Tari AM. How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci 2004;61:1475-84.
8. Hong WK, Endicott J, Itri LM, et al. 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501-5.
9. Hong Wk, Lippman SM, Itri LM, et al. Prevention of secondary primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 1990;3234:795-801.
10. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with β carotene to prevent oral carcinogenesis. N Engl J Med 1993;328:15-20.
11. Shin DM, Khuri FR, Murphy B, et al. Combined interferon-α, 13-cis-retinoic acid and α-tocopherol in locally-advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001; 19:3010-7.
12. Heo DS, Snyderman C, Gollin SM, et al. Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res 1989;49:5167-75.
13. Chikamatsu K, Nakano K, Storkus WJ, et al. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res 1999;5:1281-8.
14. + T cells. Cancer Res 2003;63:3675-81.
15. Storkus WJ, Zeh HJ, Salter RD, Lotze MT. Identification of T-cell epitopes: rapid isolation of class Ipresented peptides from viable cells by mild acid elution. J Immunother Emphasis Tumor Immunol 1993;14:94-103.
16. Asai T, Storkus WJ, Mueller-Berghaus J, et al. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from p53 and MDM-2 proteins. Cancer Immun 2002;2:3.
17. Hendrickson RC, Skipper JC, Shabanowitz J, Slingluff CJ, Jr., Engelhard VH, Hunt DF. Use of tandem mass spectrometry for MHC ligand analysis. In: Lefkovits I, editor. Immunology methods manual, vol. 2. New York: Academic Press; 1997. p. 603-10.
18. Hunt DF, Yates JR, Shabanowitz J, Winston S, Hauer CR. Protein sequencing by tandem mass spectrometry. Proc Natl Acad Sci U S A 1986;83:6233-7.
19. 264-272 peptide in cancer patients: implications for immunoselection of epitope loss variants. J Immunol 2000;165: 5938-44.
20. 264-272 epitope. J Immunol 2002;168:1338-47.
21. Magni M, Shammah S, Schiro R, Mellado W, Dalla-Favera R, Gianni AM. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 1996;87:1097-103.
22. Lopez-Albaitero A, Nayak JV, Ogino T, et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006;176:3402-9.
23. Storms RW, Green PD, Stafford KM, et al. Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34. Blood 2005;106:95-102.
24. Chute JP, Muramoto GG, Whitesides J, et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci U S A 2006;103:11707-12.
25. Donnenberg VS, Donnenberg AD. Identification, rare-event detection and analysis of dendritic cell subsets in broncho-alveolar lavage fluid and peripheral blood by flow cytometry. Front Biosci 2003;8:1175-80.
26. Donnenberg AD, Koch EK, Griffin DL, et al. Viability of cryopreserved bone marrow (BM) progenitor cells stored for more than a decade. Cytotherapy 2002;4:157-63.
27. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-6.
28. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999;10:673-9.
29. Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 2002;133:118-23.
30. Danet-Desnoyers GA, Luongo JL, Bonnet DA, Domchek SM, Vonderheide RH. Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. Exp Hematol 2005;33:1275-80.
31. Li L, Giannopoulos K, Reinhardt P, et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int J Oncol 2006;28:855-61.
32. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2004;54: 187-207.
33. Sladek NE, Kollander R, Sreerama L, Kiang DT. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 2002; 49:309-21.
34. Takebe N, Zhao SC, Adhikari D, et al. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. Mol Ther 2001;3:88-96.
35. Moreb JS, Gabr A, Vartikar GR, Gowda S, Zucali JR, Mohuczy D. Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde. J Pharmacol Exp Ther 2005;312:339-45.
36. Le Moguen K, Lincet H, Deslandes E, et al. Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10. Proteomics 2006;6:5183-92.
37. Lango M, Wentzel AL, Song JI, et al. Responsiveness to the retinoic acid receptor-selective retinoid LGD1550 correlates with abrogation of transforming growth factor α/epidermal growth factor receptor autocrine signaling in head and neck squamous carcinoma cells. Clin Cancer Res 2003;9:4205-13.
38. Epping MT, Bernards R. A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res 2006;66:10639-42.
39. Khuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2000;98:441-50.